Overview

* Intellia Q2 collaboration revenue rises to $14.2 mln from $6.9 mln yr ago

* Net loss narrows to $101.3 mln from $147.0 mln yr ago

* Co progressing ahead of schedule in Phase 3 trials for ATTR amyloidosis and HAE

Outlook

* Company expects cash reserves to fund operations into H1 2027

Result Drivers

* COLLABORATION REVENUE - Increase due to cost reimbursements from Regeneron Pharmaceuticals collaboration

* COST DECLINE - R&D and G&A expenses dwcline year over year due to lower stock-based compensation, among other reasons

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $14.24

Collabor mln

ation

Revenue

Q2 Net -$101.26

Income mln

Q2 Basic -$0.98

EPS

Q2 $124.24

Operatin mln

g

Expenses

Q2 -$110

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Intellia Therapeutics Inc ( NTLA ) is $30.00, about 62.1% above its August 6 closing price of $11.37

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)